FDA Literature Review – Class III PMS and Indication Expansion

Introduction

Why FDA increasingly expects robust literature evidence for Class III devices

For Class III medical devices, the U.S. Food and Drug Administration increasingly expects manufacturers to demonstrate device safety and effectiveness using a totality-of-evidence approach [21 CFR 814.20]. While clinical investigations remain central to Premarket Approval (PMA) pathways, FDA has made it clear that published scientific literature is a critical supporting data source—particularly when assessing long-term safety, post-market performance, and evolving risk profiles [21 CFR 814.20(b)(3)(ii)].

For manufacturers, this shift means that literature reviews are no longer a secondary or informal exercise. FDA expects literature evidence to be systematically identified, critically evaluated, and transparently documented, particularly for high-risk Class III devices [FDA, Scientific Evidence in Medical Device Submissions, Guidance for Industry and FDA Staff (Dec 2017)].

Distinction from EU MDR / CER literature requirements

Although literature reviews are also central to EU Medical Device Regulation (MDR) Clinical Evaluation Reports (CERs), FDA expectations differ materially in both purpose and structure.

EU MDR literature reviews are typically framed around demonstrating conformity with General Safety and Performance Requirements (GSPRs) and supporting an ongoing clinical evaluation narrative. In contrast, FDA literature reviews are submission-specific and question-driven, designed to support discrete regulatory decisions such as PMA approval, post-approval commitments, or label modifications.

While FDA requirements differ, the fundamentals of a rigorous EU MDR literature review apply across most regulatory frameworks — [read our guide].

FDA reviewers focus less on exhaustive narrative summaries and more on whether the literature:

• Directly addresses defined safety or effectiveness questions

• Is methodologically sound and appropriately selected

• Complements, rather than substitutes for, clinical and post-market data

Who this guide is for

This guide is intended for:

· Regulatory Affairs professionals managing PMA submissions, supplements, and post-approval obligations

· Clinical Affairs teams responsible for evidence generation, surveillance, and indication expansion strategies

· Medical writers and evidence teams conducting FDA-ready literature reviews for Class III devices

It provides practical, FDA-specific guidance on when literature reviews are required, how they are evaluated, and how to design reviews that withstand regulatory scrutiny.

When FDA Requires Literature Reviews

FDA does not prescribe a single, standardized literature review format. Instead, literature evidence is expected in defined regulatory contexts where published data can meaningfully inform safety, effectiveness, or ongoing risk assessment.

PMA submissions and PMA supplements

Literature reviews are commonly included as supportive evidence within Premarket Approval (PMA) submissions, particularly when:

• The device technology has prior clinical use or published experience

• Related or comparable technologies have generated safety or performance data

• Long-term outcomes extend beyond the duration of pivotal clinical trials

For PMA supplements — including design changes, manufacturing modifications, or labeling updates — FDA may expect updated literature searches to confirm that new information does not alter the established benefit–risk profile [21 CFR 814.39].

522 Postmarket Surveillance Studies

Under Section 522 of the Federal Food, Drug, and Cosmetic Act, FDA may require manufacturers to conduct postmarket surveillance studies to address specific safety or effectiveness concerns [21 U.S.C. § 360l; 21 CFR Part 822].

In this context, literature reviews may support:

• Background risk assessments
• Identification of known or emerging adverse events
• Justification of study design, endpoints, or duration

For higher-risk Class III devices, ongoing literature monitoring may form part of broader postmarket surveillance and lifecycle compliance expectations.

Indication expansion and label changes

When manufacturers seek expanded indications for use or labeling modifications, published studies may supplement new clinical data [21 CFR 814.39].

Literature may help:

• Demonstrate clinical experience in broader or adjacent patient populations
• Support biological or mechanistic plausibility
• Contextualize outcomes relative to existing approved indications

However, FDA evaluates whether the literature is sufficiently device-specific and methodologically robust. Where proposed indications introduce new risks or substantially different patient populations, literature is expected to supplement — not replace — new clinical investigations.

Annual reports and post-approval obligations

For approved Class III devices, FDA may expect literature evidence as part of annual reports or post-approval study updates [21 CFR 814.84].

These reviews support ongoing safety surveillance by identifying:

• Newly published adverse events
• Shifts in clinical practice or device utilization
• Emerging comparative effectiveness data

Real-world evidence expectations

FDA’s authority to incorporate real-world evidence (RWE) into regulatory decision-making was reinforced under the 21st Century Cures Act [21st Century Cures Act § 3022]. Subsequent FDA guidance further clarifies expectations for relevance, reliability, and methodological rigor when real-world evidence is used to support regulatory decisions.

For Class III devices, manufacturers are expected to critically appraise published real-world data and clearly articulate how it informs regulatory decision-making within the context of safety and effectiveness.

FDA-Specific Literature Review Requirements

Applicable FDA guidance documents

FDA does not issue a single guidance dedicated exclusively to literature reviews. Instead, expectations are embedded across guidances addressing scientific evidence, PMA submissions, post-approval studies, and real-world evidence.

Notably, the FDA guidance Scientific Evidence in Medical Device Submissions (2017) outlines principles for evaluating the relevance, reliability, and methodological quality of published data submitted in support of regulatory decisions.

Together, these documents establish that literature evidence must be:

• Relevant to the regulatory question
• Scientifically valid and methodologically sound
• Transparently documented and reproducible.

Systematic vs. targeted literature reviews

FDA does not require all literature reviews to follow a fully systematic methodology. The level of rigor depends on the regulatory context and the role literature plays in the evidence package.

Systematic literature reviews are most appropriate when:

• When literature serves as a primary evidence source
• When supporting indication expansion
• When evaluating long-term safety or rare adverse events

In such cases, predefined inclusion criteria, structured screening, and transparent documentation are expected. PRISMA-aligned principles are commonly used to demonstrate methodological rigor.

Targeted literature reviews may be appropriate for focused updates, such as confirming the absence of newly reported adverse events or updating prior submissions.

Regardless of approach, manufacturers should justify the selected methodology based on the regulatory objective.

Search strategy documentation expectations

FDA places significant emphasis on transparency and reproducibility of search methodology.

Literature reviews submitted in regulatory contexts should clearly document:

• Databases searched
• Date ranges covered
• Complete search strings and Boolean logic
• Inclusion and exclusion criteria

Clear documentation allows FDA reviewers to assess whether the search was appropriately comprehensive and relevant to the regulatory question.

Screening and Study Selection

Manufacturers should describe:

• The screening process used

• Rationale for excluding studies

• How final study inclusion was determined

PRISMA-style flow diagrams may be helpful in illustrating study selection, particularly when literature plays a substantial role in the regulatory evidence package.

Critical Appraisal and Regulatory Relevance

In an FDA context, critical appraisal focuses on regulatory relevance rather than academic critique alone.

Manufacturers should assess:

• Study design and potential bias

• Endpoint relevance to the device’s intended use

• Applicability to the approved or proposed patient population

The goal is not to summarize literature descriptively, but to determine whether published data meaningfully support the regulatory question being addressed.

Synthesis and Gap Analysis

Literature findings should be synthesized in a manner that directly answers defined safety or effectiveness questions.

Where evidence gaps exist, manufacturers should:

• Acknowledge limitations

• Explain why the available evidence remains sufficient, or

• Identify additional data sources used to mitigate uncertainty

This structured approach strengthens regulatory defensibility and reduces the likelihood of review deficiencies.

PRISMA alignment for FDA submissions

Although PRISMA was developed for academic systematic reviews, its transparency principles are often useful in FDA regulatory contexts when literature plays a significant evidentiary role.

Structured reporting elements — such as documented screening steps, clear inclusion and exclusion criteria, and flow diagrams summarizing study selection — can enhance methodological clarity and reduce ambiguity during FDA review.

Importantly, FDA does not require academic publication formatting. However, applying PRISMA-aligned principles can strengthen transparency and reproducibility when literature serves as a substantive component of the regulatory evidence package.

Literature for Post-Market Surveillance (Deep Dive)

Ongoing safety monitoring through published literature

For Class III medical devices, post-market surveillance (PMS) extends beyond formal adverse event reporting systems and post-approval studies. FDA expects manufacturers to actively monitor published scientific literature as part of ongoing safety oversight.

Peer-reviewed publications can reveal safety trends that may not yet be apparent through internal complaint handling or Medical Device Reporting (MDR) systems. These may include:

• Delayed or cumulative adverse events

• Rare complications emerging with broader clinical use

• Device interactions identified in real-world practice

As a result, literature monitoring is increasingly viewed by FDA as a proactive risk management activity, rather than a retrospective documentation exercise.

Signal detection from published adverse events

One of the primary regulatory purposes of post-market literature review is signal detection. Case reports, case series, observational studies, and registry publications may describe adverse events that warrant further evaluation, even when event rates are low or causality is uncertain.

FDA expects manufacturers to demonstrate that they:

• Routinely screen literature for device-related adverse events

• Assess clinical relevance and plausibility

• Escalate credible signals through internal risk management processes

Importantly, FDA does not require every published adverse event to trigger regulatory action. However, manufacturers should document how literature signals are evaluated, trended, and resolved, including justification when no further action is deemed necessary.

Integrating literature with MDR and complaint data

Literature findings should not be evaluated in isolation. FDA expects manufacturers to integrate published evidence with internal data sources, including:

• MDR submissions

• Complaint handling records

• Post-approval or postmarket study data

This integrated approach allows manufacturers to assess whether signals observed in the literature are consistent with internal experience or represent emerging risks.

For example, a complication reported sporadically in published case series may take on greater significance if similar events are identified in complaint data. Conversely, literature-reported events that are not corroborated internally may still require documentation and rationale explaining their limited relevance to the device’s approved use.

Frequency and update expectations

FDA does not prescribe a fixed frequency for literature review updates across all Class III devices. Instead, expectations are risk-based and context-dependent.

Factors influencing review frequency include:

• Device risk profile and intended use

• Severity and reversibility of potential adverse events

• Extent of real-world utilization

• Existence of post-approval study or 522 requirements

Literature Supporting Indication Expansion

Building evidence packages from published studies

When manufacturers seek expanded indications for use, literature reviews often play a critical role in supporting the regulatory rationale. FDA expects literature evidence to contribute to a coherent evidence package, rather than function as a standalone justification.

Published studies may be used to:

• Demonstrate clinical experience in broader or adjacent populations

• Support biological or mechanistic plausibility for expanded use

• Provide long-term or real-world outcomes not captured in new trials

FDA evaluates literature in this context based on relevance, quality, and applicability to the proposed indication, with particular attention to patient population alignment and clinical endpoints.

Handling off-label use literature

Literature describing off-label use can be informative, but it requires careful interpretation. FDA generally permits consideration of off-label literature as contextual evidence, provided manufacturers clearly distinguish:

• Approved versus unapproved use scenarios

• Differences in patient populations, dosing, or procedural technique

• Limitations related to study design or intent [21 CFR 814.39].

Manufacturers should avoid overstating conclusions drawn from off-label studies and should clearly explain how such data supports, but does not replace, required clinical evidence.

Comparator device literature strategies

In some indication expansion cases, direct device-specific literature may be limited. FDA may allow manufacturers to reference comparator or similar device literature to contextualize expected performance or risk profiles.

When using comparator literature, manufacturers should justify:

• Technological similarity and intended use alignment

• Differences in materials, design, or mode of action

• Relevance of reported outcomes to the subject device

Clear rationale is essential to avoid inappropriate extrapolation.

When literature alone is insufficient

FDA generally does not accept literature evidence as the sole basis for indication expansion when:

• The proposed indication introduces new risks

• Patient populations differ substantially from those previously studied

• Outcomes are subjective or highly operator-dependent

In these scenarios, literature is expected to supplement, not replace, new clinical investigations.

Practical Workflow: Conducting FDA-Ready Literature Reviews

Database selection

FDA expects literature reviews to be conducted using appropriate and comprehensive databases, selected based on the clinical and regulatory question being addressed.

Commonly used sources include:

• PubMed / MEDLINE

• Embase

• FDA databases and advisory committee materials

Manufacturers should justify database selection and demonstrate that key sources relevant to the device and indication were included.

Search string documentation

Search strategies should be predefined, documented, and reproducible. FDA reviewers may assess whether search terms were sufficiently sensitive to capture relevant evidence. [FDA, Scientific Evidence in Medical Device Submissions (Dec 2017)]

Documentation typically includes:

• Full search strings and Boolean operators

• Date ranges

• Filters or limits applied

Well-documented searches reduce ambiguity and support regulatory confidence.

Screening and selection process

FDA expects manufacturers to clearly describe how studies were screened and selected. This includes:

• Defined inclusion and exclusion criteria

• Rationale for study exclusion

• Documentation of screening decisions (eg PRISMA-aligned reporting).

PRISMA-style flow diagrams are often useful for illustrating the screening process, even when a fully systematic review is not required.

Critical appraisal in an FDA context

Critical appraisal should focus on regulatory relevance, not academic critique alone. FDA reviewers are primarily interested in whether study limitations impact the reliability of conclusions drawn for safety or effectiveness.

Manufacturers should assess:

• Study design and bias

• Outcome relevance

• Applicability to the device’s approved or proposed use

Synthesis and gap analysis

Literature findings should be synthesized to answer specific regulatory questions, rather than summarized descriptively. Identified gaps should be acknowledged and addressed through additional data sources where appropriate.

How Evidence Cloud Supports FDA Literature Requirements

Managing FDA-ready literature reviews requires tools that support traceability, transparency, and ongoing updates. Platforms such as Evidence Cloud are designed to align with these regulatory expectations. These features help translate regulatory expectations into operationally consistent literature workflows.

Key capabilities include:

• Multi-database search management, enabling structured and repeatable searches

• Audit trails documenting search strategies, screening decisions, and updates

• Living review functionality to support ongoing PMS and post-approval obligations

These features can help regulatory and clinical teams maintain consistent, inspection-ready literature processes across the device lifecycle.

Conclusion

Key takeaways

For Class III medical devices, literature reviews are an increasingly important component of FDA regulatory strategy. They support:

• PMA submissions and supplements

• Postmarket surveillance and 522 compliance

• Indication expansion and labeling updates

FDA expects literature evidence to be purpose-driven, methodologically sound, and transparently documented.

Moving toward standardized, FDA-ready processes

By aligning literature review workflows with FDA expectations—rather than repurposing EU MDR methodologies—manufacturers can reduce regulatory friction and improve evidence quality across submissions.

Standardized processes, supported by appropriate tools and documentation practices, help ensure that literature evidence remains current, defensible, and actionable throughout the product lifecycle.

As FDA continues to emphasize real-world performance and lifecycle oversight, literature reviews will remain a foundational element of Class III regulatory strategy.

Optional companion resources

Manufacturers may benefit from developing internal tools such as:

• An FDA Literature Review Checklist

• Standard operating procedures for PMS literature monitoring

• Templates for indication expansion evidence summaries

These resources can further support regulatory readiness and cross-functional alignment.